RESUMO
PURPOSE OF REVIEW: Recent findings in the influence of dietary patterns, dairy products, beverages and microbiota composition and function on bone health are reviewed and discussed. RECENT FINDINGS: Evidence is accumulating on the increased risk of fracture in individuals following a vegan diet. Meta-analysis of randomized controlled trials indicates a favourable, though of low amplitude, effect of dairy products on bone mass accrual during childhood and adolescence. Though mostly based on results from observational studies, it seems that dairy product consumption, particularly fermented dairy products, is associated with a lower risk of hip fracture. Regular green tea drinkers may have a lower fracture risk than tea abstainers. Magnesium intake is beneficial for bone health. Prune supplements prevents bone loss in untreated postmenopausal women. This seems to be associated with modification of gut microbiota. SUMMARY: This information should help the medical practitioners facing questions from their patients on how to protect bone health through nutrition.
Assuntos
Densidade Óssea , Fraturas do Quadril , Adolescente , Humanos , Feminino , Laticínios , Osso e Ossos , Fraturas do Quadril/prevenção & controle , BiologiaRESUMO
The sequential effects of romosozumab and denosumab in osteoporosis are shown in real-life, while the mechanisms of post-denosumab rebound are reviewed extensively. A network meta-analysis confirms the superiority of anabolics vs anti-resorptives on fracture reduction, while the latter shown a reduction of mortality in a large population-based study. Fracture risk prediction by FRAXPlus is improved. New meta-analyses confirm the benefits of Vitamin D on fractures and falls. Finally, multiples trials with new molecules for the treatment of rare bone diseases, including osteogenesis imperfecta, fibrous dysplasia and hypoparathyroidism, shown promising results.
Dans l'ostéoporose, les effets séquentiels du romosozumab et du dénosumab se précisent et les mécanismes du rebond à l'arrêt de ce dernier font l'objet d'une revue détaillée. Une méta-analyse en réseau confirme la supériorité des traitements anaboliques sur les antirésorbtifs, alors que l'effet de ces derniers sur la réduction de la mortalité est démontré dans une large étude populationnelle. La prédiction du risque fracturaire est améliorée par l'outil FRAXPlus. De nouvelles méta-analyses des bénéfices de la vitamine D sur le risque de fractures et de chutes sont également disponibles. Enfin, de nombreuses études encourageantes sur l'efficacité de nouveaux traitements dans de multiples maladies osseuse rares, telles l'ostéogenèse imparfaite, la dysplasie fibreuse et l'hypoparathyroïdie, ont été publiées.
Assuntos
Doenças Ósseas Metabólicas , Fraturas Ósseas , Hipoparatireoidismo , Osteoporose , Humanos , Denosumab/uso terapêutico , Doenças Ósseas Metabólicas/tratamento farmacológico , Fraturas Ósseas/epidemiologia , Fraturas Ósseas/etiologia , Doenças RarasRESUMO
Bone mass and strength achieved at the end of the growth period, simply designated as "Peak Bone Mass (PBM)", plays an essential role in the risk of osteoporotic fractures occurring in adulthood. It is considered that an increase of PBM by one standard deviation would reduce the fracture risk by 50 percent. As estimated from twin studies, genetics is the major determinant of PBM, accounting for about 60 to 80 percent of its variance. During pubertal maturation, the size of the bone increases whereas the volumetric bone mineral density remains constant in both genders. At the end of puberty, the sex difference is essentially due to a greater bone size in male than female subjects. This is achieved by larger periosteal deposition in boys, thus conferring at PBM a better resistance to mechanical forces in men than in women. Sex hormones and the IGF-1 system are implicated in the bone sexual dimorphism occurring during pubertal maturation. The genetically determined trajectory of bone mass development can be modulated to a certain extent by modifiable environmental factors, particularly physical activity, calcium and protein intakes. Prepuberty appears to be an opportune time to modify environmental factors that impinge on bone mineral mass acquisition.
La masa y fortaleza ósea conseguida al final del periodo de crecimiento, designada simplemente como masa ósea máxima (MOM), constituye un factor crítico en cuanto al riesgo de fracturas osteoporóticas en la edad adulta. Se considera que un aumento de MOM de una desviación estándar reduciría el riesgo de fracturas en 50 por ciento. Los estudios en gemelos han mostrado que la genética es el principal determinante de MOM, siendo responsable de 60 a 80 por ciento de su variación. Durante la maduración puberal el tamaño de los huesos aumenta mientras que su densidad mineral volumétrica permanece constante en ambos géneros. Al final de la pubertad la diferenciación sexual se debe básicamente al mayor tamaño de los huesos en hombres que en mujeres. Esto se consigue mediante una mayor deposición periosteal en los muchachos, confiriéndole así a la MOM mayor resistencia a las fuerzas mecánicas en hombres que en mujeres. Este dimorfismo sexual óseo que se presenta durante la maduración puberal se debe sobre todo a las hormonas sexuales y al factor de crecimiento insulínco 1 (IGF-1). La trayectoria genéticamente determinada de desarrollo de la masa ósea puede modularse hasta cierto punto mediante factores ambientales modificables, sobre todo la actividad física y la ingesta de calcio y proteínas. El periodo prepuberal parece ser el momento oportuno para modificar los factores ambientales que afectan la adquisición de masa mineral ósea.